Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

615.O3.8 Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
3020-3022-3024 - West (Moscone Center)
Moderators:
Geoffrey Uy and Martin Carroll, MD
7:00 AM
Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group

Arnaud Pigneux, MD, PhD1*, Francis Witz2*, Mathieu Sauvezie3*, Marie-Christine Bene, MD, PhD4*, Isabelle Luquet, MD, PhD5*, Mathilde hunault-Berger, MD, PhD6*, Christian Recher, M.D;, Ph.D7*, Norbert Vey, MD8, Bruno Lioure, MD9*, Chantal Himberlin, MD10*, Martine Escoffre-Barbe, MD11*, Christian Berthou12*, Severine Lissandre13*, Nathalie Fegueux, MD14*, Jean-Yves Cahn, MD, PhD15, Eric Jourdan, MD, PhD16*, Didier Bouscary, MD, PhD17*, Francois Dreyfus18*, Josy M. Reiffers19*, Noel Milpied, MD20*, Jean-Luc Harousseau, MD21* and Norbert Ifrah, MD22

1CHU Bordeaux, Bordeaux, France
2Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
3Hematology, CHU de Bordeaux, Bordeaux, France
4Immunologie, Faculté de Médecine, Nancy, France
5Laboratoire central d'Hématologie, Hôpital Robert Debré, Reims, France
6Maladies du sang, CHU, Angers, France
7Service d'Hematologie, CHU Toulouse, Toulouse, France
8Dept. of Hematology, Institut Paoli Clamettes, Marseille, France
9Oncology and Hematology, Hopital de Hautepierre, Strasbourg Cedex, France
10Unité d'hématologie clinique, Hôpital Robert Debré, Reims, France
11Hématologie clinique, Hôpital Pontchaillou, Rennes, France
12CHU Brest, Brest, France
13Service d'Hematologie - Transplantation, CHU Saint - Louis - APHP, Paris, France
14Service Oncologie et Hématologie, Hôpital Lapeyronie, Montpellier, France
15Hematology Department, CHU de Grenoble, Grenoble, France
16Médecine B – Unité Onco-Hématologie, Hôpital Caremeau, Nimes, France
17Hematologie, Institut Cochin, Paris, France
18Hematologie, CHU Cochin, Paris, France
19CRLCC Institut Bergonié, Bordeaux,, France
20Hématologie, CHU de Bordeaux, Bordeaux, France
21Département d'Hématologie, Hôpital Hôtel Dieu, Nantes, France
22Service des Maladies du Sang, CHU d'Angers, Angers, France

7:15 AM
Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial

Sergio Amadori1, Stefan Suciu2, Dominik Selleslag2, Giuliana Alimena1*, Liliana Baila2*, Vittorio Rizzoli1*, Giuseppe Rossi3, Gianluca Gaidano1, Domenico Magro1*, Giuseppe Torelli1*, Petra Muus2, Adriano Venditti1, Emma Cacciola1, Francesco Lauria4, Filip Beeldens2*, Marco Vignetti1* and Theo de Witte2

1GIMEMA Acute Leukemia Working Party, Rome, Italy
2EORTC Leukemia Group, Brussels, Belgium
3Hematology, Spedali Civili, Brescia, Italy
4University of Siena, Department of Hematology and Transplants, Siena, Italy

7:30 AM
Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study

Emmanuel Raffoux1*, Adrienne de Labarthe1*, Audrey Cras2*, Christian Recher3*, Pascal Turlure4*, Jean-Pierre Marolleau5, Oumedaly Reman6*, Claude Gardin7*, Sebastien Maury8*, Philippe Rousselot9*, Jean-Valère Malfuson10*, Odile Maarek1*, Laurent Degos1*, Christine Chomienne2* and Hervé Dombret1

1Hôpital Saint-Louis, AP-HP, Paris, France
2Inserm U718, Paris, France
3Hôpital Purpan, Toulouse, France
4CHU, Limoges, France
5Hôpital Sud, Amiens, France
6CHU, Caen, France
7Hôpital Avicenne, AP-HP, Bobigny, France
8Hôpital Henri Mondor, AP-HP, Créteil, France
9Hôpital Mignot, Versailles, France
10Hôpital Percy, Clamart, France

7:45 AM
Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/ Refractory AML

Aaron D Schimmer, MD, PhD, FRCPC1, Elihu H Estey, MD2*, Gautam Borthakur, MD2, Bing Carter, PhD2, Gary J. Schiller, MD, FACP3, Martin S. Tallman, MD4, Jessica K Altman4, Judith E. Karp, MD5, Jeannine Kassis, MD, FRCP6, Christine Jacob, MSc7*, Stephen Morris7*, Jacques Jolivet, MD, FRCP(C)7* and Michael Andreeff, MD, PhD8

1Princess Margaret Hospital, Toronto, ON, Canada
2M.D. Anderson Cancer Center, Houston, TX
3UCLA School of Medicine, Los Angeles, CA
4Northwestern University, Chicago, IL
5Johns Hopkins University, Baltimore, MD
6Maisonneuve- Rosemont Hospital, Montreal, QC, Canada
7Aegera Therapeutics Inc., Montreal, QC, Canada
8Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

8:00 AM
Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study

Xavier Thomas1*, Emmanuel Raffoux2*, Aline Renneville3*, C.écile Pautas, MD4*, Stephane de Botton5*, Thierry de Revel6*, Oumedaly Reman7*, Christine Terre8*, Claude Gardin9*, Quoc-Hung Le10*, Nathalie Philippe3*, Catherine Cordonnier, MD11, Jean-Henri Bourhis12*, Mohamed Elhamri13*, Sandrine Hayette14*, Christine Parmentier2*, Pierre Fenaux15, Sylvie Castaigne, MD16, Claude Preudhomme, PhD17 and Hervé Dombret18

1Hematologie, Hôpital Edouard Herriot, Lyon, France
2Dept. of Hematology, Hopital Saint Louis, Paris, France
3Hematology, Claude Huriez Hospital, Lille, France
4Hematology, Henri Mondor University Hospital, 94000 Creteil, France
5Groupe Francophone des Myelodysplasies (GFM), Bobigny, France
6Percy Clamart, Clamart, France
7CHU Caen, Caen, France
8CH de Versailles
9Avicenne Hospital, Bobigny, France
10Hematology, Edouard Herriot Hospital, Lyon, France
11Hematologie Clinique, Hopital Henri Mondor, Creteil, France
12Inst. Gustave-Roussy, Paris, France
13Hematology Department, Hospices Civils de Lyon, Lyon, France
14Molecular biology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
15Hématologie Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Avicenne; Paris 13 University, Bobigny, France
16Dept. Hematologie, Hopital Mignot, Le Chesnay, France
17Hopital Calmette, Lille, France
18Hopital Saint Louis AP-HP, Paris, France

8:15 AM
CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Ravindra Majeti, MD, PhD, Mark P. Chao*, Ash A. Alizadeh, MD, PhD*, Wendy W. Pang* and Irving L. Weissman, MD*

Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, CA

8:30 AM
Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jorge E. Cortes1, Darejan Ghirdaladze2*, James M. Foran3, Marcel P. DeVetten4, Mamia Zodelava5*, Mark J. Levis6, Norman M. Padre7*, James Joyce7*, Patrick P. Zarrinkar7* and Robert Corringham7*

1UT M.D. Anderson Cancer Center, Houston, TX
2Medulla Clinic, T'bilisi, Georgia
3University of Alabama at Birmingham, Birmingham, AL
4Lied Transplant Center 8718, UNMC, Omaha, NE
5Hema Clinic, T'bilisi, Georgia
6Johns Hopkins University, Baltimore, MD
7Clinical Research and Development, Ambit Biosciences Corporation, San Diego, CA

8:45 AM
Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years

Farhad Ravandi, MBBS1, Jorge Cortes, MD2, Stefan Faderl, MD2, Guillermo Garcia-Manero, MD3, Susan O'Brien, M.D.4, Gautam Borthakur, MD5, Sherry Pierce, BSN6*, Mark Brandt, BS6*, Marites Lang, RN6*, Weiguo Zhang, MD, PhD7*, Rajyalakshmi Luthra, PhD8*, Dan Jones, MD, PhD9, Mark J. Levis, MD, PhD10, Marina Konopleva, MD, PhD11, Michael Andreeff, MD, PhD12 and Hagop M Kantarjian13

1Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
2M.D. Anderson Cancer Center, Houston, TX
3Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
5Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
6Leukemia, University of Texas - M D Anderson Cancer Center, Houston, TX
7Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
8Hematopathology, University of Texas - M D Anderson Cancer Center, Houston, TX
9UT M.D. Anderson Cancer Ctr., Houston, TX
10Johns Hopkins University, Baltimore, MD
11Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
12M.D. Anderson Cancer Center, TX
13The University of Texas M. D. Anderson Cancer Center, Houston, TX

*signifies non-member of ASH